Rosetta Genomics (ROSG) Receiving Somewhat Positive Media Coverage, Accern Reports

News articles about Rosetta Genomics (NASDAQ:ROSG) have been trending somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Rosetta Genomics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.8906907541129 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Rosetta Genomics (NASDAQ:ROSG) traded down $0.02 during midday trading on Friday, reaching $0.76. The company had a trading volume of 58,391 shares, compared to its average volume of 234,598. Rosetta Genomics has a 1-year low of $0.61 and a 1-year high of $9.72. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.10 and a current ratio of 2.10.

WARNING: This piece was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Insider Buying and Selling by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply